NCT07005102

Who might be able to join this trial:

• You are generally healthy and active enough to carry out light activities, even if you cannot do heavy physical work (your doctor will assess this using a standard scale).
• You are willing to provide a tumor tissue sample — either a recent one or one stored from a previous biopsy — so it can be tested for a specific protein called c-Met before you can be assigned to a treatment group.
• You have at least one area of cancer in your body that can be measured on a scan and has not previously been treated with radiation.
• Any side effects from past cancer treatments have mostly or fully gone away (hair loss and mild nerve-related symptoms are exceptions).
• You do not have any major life-threatening conditions other than your cancer, and your doctor estimates you have a life expectancy of at least 3 months.
• You have not previously been treated with a specific type of targeted drug called an EGFR tyrosine kinase inhibitor (TKI) for advanced or spread cancer — or, if you took one after surgery to prevent cancer returning, at least 10.5 years have passed since your last dose.
• You have been formally diagnosed with a type of lung cancer called non-squamous non-small cell lung cancer (NSCLC) that has spread, and your cancer has a specific genetic change (called an EGFR mutation in Exon 19 or Exon 21), confirmed by an approved laboratory test.

Who may not be able to join:

• You have a history of a lung condition called interstitial lung disease (ILD), or inflammation of the lungs (pneumonitis) that needed treatment with steroid medicines, or your scans currently show signs of these conditions.
• You have a history of certain other lung conditions, including pulmonary fibrosis, organizing pneumonia, or drug-related lung inflammation (confirm with trial site).
• Your cancer has spread to the membranes surrounding the brain or spinal cord, or you have spinal cord compression that has not been treated with surgery or radiation.
• You have had another type of cancer in the past, unless it was fully treated at least 2 years ago with a low chance of coming back, was a successfully treated non-melanoma skin cancer, was a localised cervical carcinoma in situ, or was an early-stage breast cancer considered completely cured.

Important: Always verify eligibility with the trial site directly before applying.